RxDoctor Payments Data

Traci Ridgway

Family · Cedar Rapids, IANPI 1972265643

Payments from drug & device makers

$1,379in general payments, 2019–2025

Across 46 payments — averaging $29.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$656
  • Novartis$165
  • Merck$108
  • Pfizer$80
  • Johnson & Johnson$70
  • E.r. Squibb & Sons, L.L.C.$48
  • plus $251 from 13 others

What the payments were for

  • Food & beverage$1,379100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,379 in reported general payments places this provider in the 85th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$44,537
Medicare patients
249
Services billed
511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TasignaNilotinib Hcl13$242,434
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen57$1,194
Anastrozole41$603
Sucralfate11$486
Potassium Chloride36$476
Tamoxifen Citrate11$453
Oxycodone Hcl26$404
Morphine Sulfate13$399
Dexamethasone13$206
Tramadol Hcl47$203
Lorazepam53$185
Zolpidem Tartrate22$184
Ondansetron Hcl33$183
Acyclovir32$182
Prochlorperazine Maleate15$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisTasigna$165$242,43413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,268 family providers in Iowa.

Other family in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →